News
BCYC
13.81
-31.33%
-6.30
Optimistic Buy Rating on Bicycle Therapeutics Amidst Pipeline Promises and Differentiation Challenges
TipRanks · 2h ago
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 2h ago
Bicycle Therapeutics' Latest Trial Results Raise Questions -- Market Talk
Dow Jones · 5h ago
Bicycle Therapeutics Price Target Cut to $17.00/Share From $28.00 by B. Riley Securities
Dow Jones · 6h ago
Bicycle Therapeutics Is Maintained at Neutral by B. Riley Securities
Dow Jones · 6h ago
B. Riley Securities Maintains Neutral on Bicycle Therapeutics, Lowers Price Target to $17
Benzinga · 6h ago
Bicycle Therapeutics price target lowered to $17 from $28 at B. Riley
TipRanks · 6h ago
Candel Therapeutics, 8x8 And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Benzinga · 10h ago
Bicycle Therapeutics Lead Cancer Drug Combined With Merck's Blockbuster Drug Shows 60% Overall Response Rate In Urothelial Cancer Patients
Benzinga · 11h ago
Reported Earlier, Bicycle Therapeutics Unveils Topline Data For Zelenectide Pevedotin In Combination And Monotherapy, Expanding Focus On NECTIN4 Cancers
Benzinga · 15h ago
Bicycle Therapeutics Announces Data Updates Across Zelenectide Pevedotin Program and Development Strategy Leveraging NECTIN4 Gene Amplification
Barchart · 1d ago
Tracking Baker Brothers Portfolio - Q3 2024 Update
Seeking Alpha · 1d ago
Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
TipRanks · 3d ago
Weekly Report: what happened at BCYC last week (1202-1206)?
Weekly Report · 4d ago
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Barchart · 12/02 15:05
Weekly Report: what happened at BCYC last week (1125-1129)?
Weekly Report · 12/02 09:26
Cantor Fitzgerald biotech analyst holds an analyst/industry conference call
TipRanks · 11/29 02:45
Positive Outlook on Bicycle Therapeutics Driven by Promising Data and Upcoming Updates
TipRanks · 11/26 11:25
Relative Strength Alert For Bicycle Therapeutics
NASDAQ · 11/25 21:23
Bicycle Therapeutics to Present Data for Zelenectide Pevedotin at 2024 San Antonio Breast Cancer Symposium and Provide Program Update
Barchart · 11/25 16:30
More
Webull provides a variety of real-time BCYC stock news. You can receive the latest news about Bicycle Therapeutics Limited through multiple platforms. This information may help you make smarter investment decisions.
About BCYC
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating BT8009, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology. Its product candidates also include BT1718 and BT7455.